Skip to main content
MyDeficiencies

Corticotropin

Anterior pituitary hormone / ACTH analog

Also sold as Acthar Gel, Purified Cortrophin Gel.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Corticotropin is a 39-amino-acid peptide with a plasma half-life of about 15 minutes; the FDA label states plainly that "the pharmacokinetics of Acthar Gel have not been adequately characterized." The drug carries no CYP450 induction or inhibition, no described renal or hepatic accumulation, and no direct nutrient-transporter or enzyme-cofactor interaction of its own. Its entire pharmacologic job is to stimulate the adrenal cortex to secrete cortisol, corticosterone, and aldosterone (and, separately, to bind melanocortin receptors). That means essentially every classical nutrient and electrolyte signal in this dossier is mediated by an ACTH-induced surge in the patient's own corticosteroid hormones, not by corticotropin acting on a nutrient pathway directly. The label documents real, drug-attributable effects that mirror synthetic-glucocorticoid excess: increased renal potassium and calcium excretion, salt and water retention, decreased bone formation with increased resorption, altered glucose tolerance, and growth suppression in children. Where these findings overlap with this project's existing corticosteroid dossiers, it is because the final common pathway (glucocorticoid and mineralocorticoid receptor activation) is the same; corticotropin does not add a separate depletion mechanism on top of it.

Anterior pituitary hormone / ACTH analog · ATC H01AA01 · also sold as Acthar Gel and Purified Cortrophin Gel · reviewed September 26, 2026. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Corticotropin in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Red tier, empty

Red — Severe

See study details

No entry in this dossier reaches the red bar.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. n/a

Limits on what this shows

  • What would fill it: A prospective cohort or trial of Acthar-treated patients with paired baseline/on-treatment serum potassium, calcium, or 25-OH vitamin D, reported by treatment duration and dose, independent of the label's own pharmacovigilance data.

Why empty

Red requires two independent Tier A sources with this drug in the cohort. The label (Section 5.3, 5.13) is a genuine Tier A source for potassium, sodium/water, and calcium effects, but no second, independent interventional or observational study stratified to corticotropin/Acthar with these nutrients directly measured could be located this session, the one drug-specific RCT found (ATLANTIS, pediatric nephrotic syndrome) reported an efficacy endpoint, not electrolyte/bone outcomes, and was halted early at 31 participants.

Potassium, increased renal excretion, hypokalemia risk

Orange — Moderate

See study details

Corticotropin increases renal potassium excretion and has produced hypokalemic alkalosis in postmarketing reports; the label itself recommends considering potassium supplementation.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null findings: None identified. The ATLANTIS pediatric nephrotic syndrome trial (Wang et al. 2018, ACTH 80 U/1.73m² twice weekly, halted early at 31 patients) reported its efficacy result but the abstract accessed this session did not include electrolyte-specific safety data, a gap, not a null finding.
  • At-risk subgroups: Pre-existing renal insufficiency, hypertension, concurrent diuretic therapy, the label specifically names diuretic co-therapy as accentuating electrolyte loss (Section 7).
  • Counter-evidence: None found this session.

Regulatory status

FDA label Section 5.3 (Warnings): "Acthar Gel can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium and calcium. Dietary salt restriction and potassium supplementation may be necessary." Section 6.2 (postmarketing): hypokalemic alkalosis.

Population evidence

Label-level pharmacovigilance and prescribing guidance specific to this drug; no incidence/denominator given. This is Tier A (regulatory label, drug directly named).

Mechanism

Aldosterone and cortisol both increase distal renal tubular potassium secretion; corticotropin raises both hormones (mechanism class C, renal wasting/altered tubular handling).

Counter-evidence held on record

This is a real, drug-caused wasting effect, not a baseline dietary insufficiency. Routine potassium monitoring, not self-directed supplementation, is the appropriate response; potassium supplements carry their own hyperkalemia risk, especially with renal impairment. No specific supplement dose is recommended here; any repletion decision belongs to the prescriber.

Sodium and water retention, excess/retention direction, not a deficiency

Orange — Moderate

See study details

Corticotropin causes salt and water retention and can elevate blood pressure; this is a retention signal, and the labeled response is dietary salt restriction, never added sodium.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null findings: None found this session.
  • At-risk subgroups: Hypertension, renal insufficiency, heart failure.
  • Counter-evidence: None found this session.

Regulatory status

FDA label Section 5.3, same passage as the potassium entry. Postmarketing (Section 6.2) adds fluid retention and congestive heart failure.

Population evidence

Label-level, drug-specific (Tier A).

Mechanism

Mineralocorticoid (aldosterone) stimulation via ACTH-driven adrenal secretion (mechanism class F, hormonal/dilutional disturbance).

Counter-evidence held on record

This is an excess/retention risk (Hard Rule 5), not a nutrient deficiency. Dietary salt restriction is the labeled response; supplementation would be the hazard here, not the remedy.

Calcium, decreased absorption, increased excretion

Orange — Moderate

See study details

Corticotropin therapy is associated with decreased intestinal calcium absorption and increased calcium excretion, the mechanism the label cites behind its bone-density warning; this is distinct from osteoporosis or fracture as clinical outcomes.

Full detail, limits and 1 references

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null findings: None found. Guo W et al. 2018 (J Int Med Res, PMID 28851260) reported a potential protective effect of endogenous ACTH itself on bone mineral density in Cushing's disease compared with cortisol-secreting adrenal tumors, a mechanistic/class paper on endogenous ACTH excess, not corticotropin-treated patients, and confirmed at title level only this session. Flagged here as a genuine complicating signal rather than omitted.
  • At-risk subgroups: Pediatric patients (the label separately warns of growth/bone effects in children, the infantile-spasms population), long-duration therapy, postmenopausal women.
  • Counter-evidence: Guo et al. 2018, above, endogenous ACTH excess associated with a potential protective bone effect relative to cortisol-secreting tumors in one class-level report; this cuts against a simple "ACTH = bone loss" reading and is disclosed rather than dropped.

Regulatory status

FDA label Section 5.13: "Decrease in bone formation and an increase in bone resorption both through an effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function may occur," together with "a decrease in the protein matrix of the bone (secondary to an increase in protein catabolism) and reduced sex hormone production."

Population evidence

Label-level, drug-specific (Tier A). No separate quantitative trial with paired calcium-balance data in Acthar-treated patients was located this session.

Mechanism

Combined absorption interference, renal wasting, and direct osteoblast inhibition (mechanism classes A, C, D), the label itself separates the calcium-regulation pathway from the protein-catabolism and sex-hormone pathways.

Counter-evidence held on record

Reduced bone density and fracture are clinical outcomes, not equivalent to a diagnosed calcium deficiency (Hard Rule 2). Any calcium or vitamin D repletion decision belongs to the prescriber, calibrated to baseline levels and treatment duration. This dossier recommends no specific dose; a calcium supplement dose, if ever considered by a prescriber, should stay under the NIH Office of Dietary Supplements adult UL of 2,500 mg/day (ages 19-50) or 2,000 mg/day (over 50) from supplements plus diet combined.

Magnesium, the only drug-specific nutrient intervention located this session

Yellow — Low

See study details

In one rat study, magnesium supplementation suppressed both the oxidative-stress markers and the ex vivo DNA damage produced by protracted ACTH treatment.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None found.
  • At-risk subgroups: None established in humans.
  • Counter-evidence: None found.

Regulatory status

Not addressed in the label.

Population evidence

Đurić V et al., Magnes Res 2023, PMID 37605600, rat, ACTH-specific, title/journal/year confirmed via an opened PubMed listing page; full abstract access blocked every attempt this session (same source underlies Oxidative stress and Mitochondrial burden above, see Overlap map).

Mechanism

Not confirmed beyond the title. This dossier does not extend magnesium's general antioxidant-cofactor role in other contexts to this drug beyond what the title itself supports.

Counter-evidence held on record

Animal-only, single study, title-level access. No human dosing data exist for corticotropin patients, so no magnesium dose is recommended here. Any supplemental magnesium a reader considers independently of this drug should stay under the NIH Office of Dietary Supplements UL of 350 mg/day from supplements alone (this UL does not apply to magnesium from food).

Vitamin D, class extrapolation from the same calcium/bone mechanism

Yellow — Low

See study details

No corticotropin-specific vitamin D data exist, but a placebo-controlled trial in prednisone-treated patients, a different corticosteroid-axis drug in this project's series, found that calcium plus vitamin D3 supplementation prevented the spinal bone loss that occurred on placebo, evidence for the same glucocorticoid-calcium-vitamin D mechanism the corticotropin label already documents for calcium alone.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None found for corticotropin directly. The Buckley trial itself is a positive finding (supplementation prevented loss), which supports the mechanism rather than contradicting it.
  • At-risk subgroups: Same as the Calcium entry: pediatric patients, long-duration therapy, postmenopausal women.
  • Counter-evidence: Prednisone, not corticotropin, was the studied drug, and chronic daily oral dosing differs substantially from a repository corticotropin injection course; the cohort test fails for this drug specifically, which is why this is graded yellow rather than orange.

Regulatory status

FDA label Section 5.13 documents decreased intestinal calcium absorption and increased calcium excretion (see Calcium entry above) but does not name vitamin D specifically anywhere in the sections reviewed.

Population evidence

Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM, "Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis," Ann Intern Med 1996, PMID 8967706, DOI 10.7326/0003-4819-125-12-199612150-00004. Two-year randomized, double-blind, placebo-controlled trial, 96 rheumatoid arthritis patients on low-dose prednisone, calcium carbonate 1000 mg/day plus vitamin D3 500 IU/day versus placebo; the placebo arm lost spinal bone mineral density while the supplemented arm was protected. Prednisone, not corticotropin, was the studied drug (Tier C for this drug, class extrapolation).

Mechanism

Glucocorticoid excess is understood to impair intestinal calcium absorption partly through interference with vitamin D-dependent transport; this is the same calcium-regulation pathway (mechanism classes A, D) the corticotropin label itself names in Section 5.13, extrapolated one step further to vitamin D via a different class member's trial.

Counter-evidence held on record

This is class-level, extrapolated evidence, not a corticotropin-specific finding, and is not license to recommend a specific vitamin D dose for corticotropin patients; this dossier makes no such recommendation. Any vitamin D dose a prescriber considers should stay under the NIH Office of Dietary Supplements adult UL of 4,000 IU (100 mcg) per day.

Ungraded tier, empty

Not graded — disclosed evidence gap

See study details

Ungraded tier, empty

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. n/a

Why empty

The four entries left ungraded in the original review of this dossier (Iron, Oxygen delivery/utilization, ATP production, Vitamin D) were flagged there as compounded by real tooling limits that session, not confirmed genuine gaps. This revision re-researched all four from scratch with a dedicated tool budget (see the masthead "Updated" chip and the headline finding's tooling note) and resolved each to yellow-tier, class-level (Tier C) mechanistic evidence; see the Yellow tier above and the Overlap map below. No nutrient or category in this dossier currently meets the dual UNGRADED test of no Tier B/C evidence and no circulating claim to rebut.

What would refill it

A future nutrient or category not yet screened, or a present yellow-tier entry whose sole supporting source is later retracted or shown not to replicate, would return this tier to non-empty.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, on-target adrenal mechanism vs. a separate, less-established oxidative signal

Yellow — Low

See study details

Corticotropin's core mechanism runs through adrenocortical mitochondria (cholesterol import and steroidogenic enzyme activity); a separate, animal-only line of evidence suggests protracted ACTH exposure may also raise markers of oxidative mitochondrial/DNA damage. The two must not be conflated.

Full detail, limits and 5 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None found this session.
  • At-risk subgroups: None established beyond the rat model.
  • Counter-evidence: None found beyond the access limitation below.

Regulatory status

FDA label Section 12.1 names adrenal-cortex stimulation as the mechanism of action but gives no mitochondrial detail.

Population evidence

Entirely animal/in vitro pharmacology. Established mechanistic reviews and ACTH-specific studies: Miller WL, "Steroid hormone synthesis in mitochondria," Mol Cell Endocrinol 2013, PMID 23628605; Kimura T, "Transduction of ACTH signal from plasma membrane to mitochondria," J Steroid Biochem 1986, PMID 3027455; Igarashi Y & Kimura T, "ACTH-mediated changes in rat adrenal mitochondrial phospholipids," J Biol Chem 1984, PMID 6088515; Mukai K et al., "Cholesterol accumulation in adrenocortical mitochondria after ACTH-stimulation," Endocrinol Jpn 1984, PMID 6086296. Separately, Đurić V et al., "Magnesium suppresses in vivo oxidative stress and ex vivo DNA damage induced by protracted ACTH treatment in rats," Magnes Res 2023, PMID 37605600.

Mechanism

Named: ACTH/cAMP/PKA signaling drives StAR-mediated cholesterol import into adrenocortical mitochondria for CYP11A1-catalyzed steroidogenesis, the drug's intended, on-target action in the adrenal gland, not a systemic mitochondrial toxicity. The Đurić finding, if confirmed at full text, would represent a separate, off-target oxidative signal rather than part of this on-target mechanism.

Counter-evidence held on record

Title, journal, and year for all five sources above were confirmed via an opened PubMed search-listing page; individual abstract pages returned bot-verification challenges on every attempt this session, so exact effect sizes and tissue-level detail could not be independently confirmed beyond the listing text. See Overlap map: the Đurić source also underlies the Oxidative stress and Magnesium entries below. Do not present adrenal steroidogenic mitochondrial engagement, the drug doing its intended job, as a "burden." The caution here applies specifically to the separate, animal-only, access-limited oxidative/DNA-damage signal.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, one animal study, bidirectional relationship with steroidogenesis

Yellow — Low

See study details

A single rat study found protracted ACTH treatment raised oxidative-stress markers and ex vivo DNA damage, blunted by magnesium; a separate mechanistic line shows oxidative stress can itself suppress adrenal steroidogenesis, a reverse-direction relationship worth keeping distinct.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None found.
  • At-risk subgroups: None established in humans.
  • Counter-evidence: Abidi 2008 documents the opposite causal direction is also active in adrenal biology (oxidative stress impairing steroidogenesis), underscoring how thin the human, drug-specific picture is.

Regulatory status

Not addressed in the label.

Population evidence

Đurić V et al., Magnes Res 2023, PMID 37605600, rat, ACTH-specific (protracted treatment). Abidi P et al., "Oxidative stress-induced inhibition of adrenal steroidogenesis requires participation of p38 mitogen-activated protein kinase signaling pathway," J Endocrinol 2008, PMID 18417530, the reverse causal direction (oxidative stress affecting steroidogenesis, not the drug causing oxidative stress).

Mechanism

Not fully named beyond "disrupted balance between reactive oxygen/nitrogen species" per the Đurić title; magnesium's suppressive mechanism not confirmed beyond title-level access.

Counter-evidence held on record

Animal-only, title-level access (see Overlap map, same Đurić source as Mitochondrial burden and Magnesium). Do not present as an established human effect, and do not use this as grounds for antioxidant supplementation.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper, mechanistic signal points toward retention, not depletion

Yellow — Low

See study details

ACTH-driven cortisol secretion is a long-established inducer of hepatic ceruloplasmin, the major copper-transport acute-phase protein, so corticotropin exposure would be expected to raise, not lower, circulating copper indices. No depletion signal was found.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None found.
  • At-risk subgroups: None established.
  • Counter-evidence: The Bhathena study's causal direction is ambiguous from its title alone and is disclosed rather than resolved in either direction (Hard Rule 4).

Regulatory status

Not addressed in the label.

Population evidence

Evans GW & Wiederanders RE, "Pituitary-adrenal regulation of ceruloplasmin," Nature 1967, PMID 4293849, and "Effect of hormones on ceruloplasmin and copper concentrations in the plasma of the rat," Am J Physiol 1968, PMID 4296672, rat, ACTH/pituitary-adrenal axis specifically. Bhathena SJ et al., "Opioid Peptides, Adrenocorticotrophic Hormone and Dietary Copper Intake in Humans," Nutr Neurosci 1998, PMID 27405911, human, but the title indicates dietary copper intake as an input affecting ACTH/opioid peptide levels, i.e. a possible reverse causal direction (nutrient affecting the axis, rather than drug depleting the nutrient), which could not be confirmed either way beyond the title.

Mechanism

Cortisol/glucocorticoid-driven hepatic acute-phase protein synthesis raising ceruloplasmin and bound serum copper (adjacent to mechanism class F).

Counter-evidence held on record

If a real effect exists here it runs toward retention/elevation, not depletion (Hard Rule 5). Copper supplementation would not be an appropriate response to corticotropin therapy, and this dossier makes no such recommendation.

Iron, reverse-direction finding, class extrapolation

Yellow — Low

See study details

A 2026 mechanistic study found that glucocorticoids, the hormone class corticotropin causes the adrenal cortex to secrete, stimulate iron mobilization and utilization via bone-marrow macrophages to fuel erythropoiesis, and that glucocorticoid therapy "restores iron metabolism" in autoimmune hemolytic anemia; no depletion signal was found for this drug or its hormone class.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: No source located this session shows corticotropin or ACTH lowering serum iron, ferritin, or transferrin saturation in a standard, non-anemia population.
  • At-risk subgroups: Not a depletion-risk population; the mechanism is disease-context-specific (autoimmune hemolytic anemia and other glucocorticoid-responsive anemias), not a general finding for corticotropin patients.
  • Counter-evidence: General-glucocorticoid, disease-context mechanistic finding; ACTH/corticotropin itself was not the studied agent, so the cohort test fails for this drug specifically. Does not generalize to a typical corticotropin patient's iron status.

Regulatory status

Not addressed in the corticotropin label.

Population evidence

Li M, Wang Y, Huang H, Sun H, Gao M, et al., "CD163+ macrophages coordinate erythroblastic Island formation and iron metabolism to enable glucocorticoid-induced erythropoiesis," Biomarker Research 2026, DOI 10.1186/s40364-026-00936-w. Single-cell sequencing, molecular assays, mouse models, and ex vivo bone marrow from autoimmune hemolytic anemia patients; general glucocorticoid exposure, not corticotropin/ACTH administration itself (Tier C for this drug, class extrapolation).

Mechanism

CD163-positive macrophages increase iron-handling capacity under glucocorticoid exposure and coordinate erythroblastic island architecture; CD163-deficient mice show impaired iron handling and reduced glucocorticoid-driven erythropoiesis (mechanism classes I and F, increased utilization and hormonal disturbance, in the retention/utilization direction rather than depletion).

Counter-evidence held on record

If a real effect exists for this drug it would run toward iron utilization/retention, not depletion (Hard Rule 5). This is a stimulatory, disease-context mechanism, never grounds for iron supplementation or for expecting corticotropin to affect iron status in ordinary use. See Overlap map: this same source underlies the Oxygen delivery/utilization entry below.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, one on-indication study, access-limited

Yellow — Low

See study details

A 2023 study reported Clostridioides (gut microbiome) abnormalities in relation to ACTH treatment efficacy in infantile epileptic spasm syndrome, corticotropin's own labeled pediatric indication, and the most directly on-point of the seven category searches this session, though full-text access was blocked.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None found.
  • At-risk subgroups: Infants and young children, the label's own infantile-spasms population.
  • Counter-evidence: None found.

Regulatory status

The label separately documents increased infection risk with any pathogen (viral, bacterial, fungal) during corticotropin therapy (Section 5.1), an immunosuppression-driven infection-risk warning, kept distinct from microbiome composition itself.

Population evidence

Wan Y et al., "Clostridioides abnormalities and ACTH treatment efficacy in infantile epileptic spasm syndrome," CNS Neurosci Ther 2023, PMID 37553527, title-level confirmed via an opened PubMed listing page; full abstract blocked (persistent bot-verification) every attempt this session, so taxa, direction, and sample size could not be independently confirmed.

Mechanism

Not confirmed beyond title. Plausible pathways include cortisol-driven immune modulation and/or a bidirectional gut-brain-HPA axis relationship (mechanism class G).

Counter-evidence held on record

Title-level access only; do not present as confirmed dysbiosis pending full-text verification, and do not conflate with the separate, label-based infection-risk warning above.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization, reverse-direction finding, class extrapolation

Yellow — Low

See study details

Glucocorticoids, the hormone class corticotropin stimulates the adrenal cortex to secrete, are established therapy for Diamond-Blackfan anemia, a red-cell aplasia, via stimulation of erythroid progenitor expansion; this is a stimulatory mechanism on oxygen-carrying capacity in a specific disease context, not a deficiency, and not corticotropin-specific.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: No source located this session shows corticotropin or ACTH lowering hemoglobin, hematocrit, or red-cell mass in a standard, non-anemia population.
  • At-risk subgroups: Not a deficiency-risk group; this mechanism is exploited therapeutically in specific red-cell aplasias and autoimmune hemolytic anemia, not evidence that ordinary corticotropin patients see improved oxygen delivery.
  • Counter-evidence: General-glucocorticoid, disease-context pharmacology; ACTH/corticotropin itself was not the studied agent in either source, so the cohort test fails for this drug specifically. Per Hard Rule 2, any oxygen-delivery change in a corticotropin patient with an unrelated clinical diagnosis would be an outcome, not a nutrient-style finding, and none is implied here.

Regulatory status

Not addressed in the corticotropin label; the label documents increased infection risk (Section 5.1) but not hematologic parameters.

Population evidence

Macečková Z, Kubíčková A, De Sanctis JB, Hajdúch M, "Effect of Glucocorticosteroids in Diamond-Blackfan Anaemia: Maybe Not as Elusive as It Seems," Int J Mol Sci 2022, PMID 35163808, DOI 10.3390/ijms23031886, a narrative review of glucocorticoid mechanisms in this red-cell aplasia, general glucocorticoid class, established first-line therapy. Li M et al. 2026 (above, DOI 10.1186/s40364-026-00936-w) mechanistically ties glucocorticoid exposure to erythroblastic island formation via CD163+ macrophages.

Mechanism

Glucocorticoid receptor signaling in erythroid progenitors promotes burst-forming-unit erythroid (BFU-E) self-renewal and expansion, secondarily supported by macrophage-mediated erythroblastic island formation (mechanism classes F and I).

Counter-evidence held on record

This is the hormone class's own pharmacologic mechanism in specific disease contexts, not a nutrient-style oxygen-delivery deficiency or surplus claim for ordinary corticotropin use (Hard Rule 2 and Hard Rule 5 framing). See Overlap map: shares the Li et al. 2026 source with the Iron entry above.

ATP production, class extrapolation, directionally mixed evidence by dose and duration

Yellow — Low

See study details

Class-level glucocorticoid literature points two directions depending on exposure: one rat/cultured-cell study found glucocorticoid receptor activation stimulates skeletal-muscle mitochondrial biogenesis and cytochrome c oxidase activity, while a chronic dexamethasone-induced myopathy model found reduced measured ATP content; neither study used corticotropin or ACTH itself.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: Weber 2002 explicitly reports no change in respiratory-chain coupling state despite the biogenesis signal, a partial null on efficiency even as capacity increased.
  • At-risk subgroups: Chronic, high-dose corticosteroid exposure associated with clinically evident steroid myopathy; no corticotropin-specific dosing data exist to define an at-risk threshold for this drug.
  • Counter-evidence: Neither study used corticotropin or ACTH; both used a different glucocorticoid administered directly rather than induced via ACTH secretion, so the cohort test fails for this drug specifically. The two sources also point in different directions from each other, which is disclosed here rather than resolved in either direction (Hard Rule 4 and Step 5).

Regulatory status

Not addressed in the corticotropin label.

Population evidence

Weber K, Bruck P, Mikes Z, Kupper J, Klingenspor M, Wiesner R, "Glucocorticoid hormone stimulates mitochondrial biogenesis specifically in skeletal muscle," Endocrinology 2002, 143(1):177-184, DOI 10.1210/en.143.1.177, rat and cultured mouse cells: high circulating glucocorticoid stimulated mitochondrial DNA transcription and cytochrome c oxidase activity in skeletal muscle, blocked by the glucocorticoid-receptor antagonist RU486, without a change in respiratory-chain coupling state. Shi J, Ge H, Yang Z, Zhan H, "Qigu capsule alleviates dexamethasone-induced muscle dysfunction through mitochondrial biogenesis," J Tradit Chin Med 2025, PMID 40810219, DOI 10.19852/j.cnki.jtcm.2025.04.004, mouse model: dexamethasone 1 mg/kg intraperitoneally daily for six weeks reduced rotarod performance, mitochondrial ultrastructure, respiratory chain complex V activity, and measured ATP content, reversed by a PGC-1alpha/AMPK-activating compound. Both are Tier C for corticotropin, class extrapolation, general glucocorticoid rather than ACTH administration.

Mechanism

Glucocorticoid receptor signaling directly affects mitochondrial biogenesis and electron-transport-chain component activity in skeletal muscle (mechanism class E); the direction, increased biogenesis and oxidase activity in Weber's shorter-exposure rat model versus reduced ATP content in Shi's six-week high-dose dexamethasone atrophy model, appears to depend on dose and duration rather than reflecting one uniform effect.

Counter-evidence held on record

Do not present this as either a confirmed ATP deficiency or a confirmed benefit; the directionally mixed, dose- and duration-dependent, class-level evidence does not support any supplement or dosing claim for corticotropin patients.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • "Corticotropin/Acthar is not itself a steroid, so it avoids the nutrient and metabolic effects of prednisone-type corticosteroids."

    Where it comes from: General patient/consumer framing that trades on corticotropin's marketing and administrative separation from synthetic corticosteroids (it is discussed and dosed apart from prednisone, methylprednisolone, and similar drugs, and is sometimes presented as a gentler alternative).

    Why it fails: The FDA label directly documents salt and water retention, increased potassium and calcium excretion, altered glucose tolerance, decreased bone density with growth suppression in children, and Cushingoid-type adverse effects (Sections 5.3, 5.12, 5.13, 6.2), the same downstream picture as glucocorticoid excess, because corticotropin's approved mechanism is to raise the patient's own cortisol. The molecule differs from a synthetic corticosteroid; the metabolic consequence for the patient does not.

All references used above
  1. Acthar Gel (Repository Corticotropin Injection), FDA prescribing information. — Mallinckrodt ARD LLC, via DailyMed. Sections 1, 2, 5, 6, 7, 12 opened in full.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, code H01AA01, Corticotropin. — DDD 25 U, parenteral (P).
  3. DailyMed search listing for "corticotropin." — Confirms Acthar Gel (Mallinckrodt ARD LLC) and Purified Cortrophin Gel (ANI Pharmaceuticals) as the two repository-corticotropin brand products.
  4. Wang CS, Travers C, McCracken C, et al. Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial. — Clin J Am Soc Nephrol, 2018. PMID 30442868, DOI 10.2215/CJN.06890618. RCT, 31 participants enrolled before early stop for futility; ACTH 80 U/1.73m² twice weekly ineffective at preventing relapse vs. control. Abstract opened via the Semantic Scholar API.
  5. Đurić V, et al. Magnesium suppresses in vivo oxidative stress and ex vivo DNA damage induced by protracted ACTH treatment in rats. — Magnes Res, 2023. PMID 37605600.Title/journal/year confirmed via an opened PubMed search-listing page; the individual abstract page returned a bot-verification challenge on every attempt this session and could not be read.
  6. Wan Y, et al. Clostridioides abnormalities and ACTH treatment efficacy in infantile epileptic spasm syndrome. — CNS Neurosci Ther, 2023. PMID 37553527.Title-level only; the abstract page was blocked by bot-verification and the Europe PMC/Semantic Scholar lookups were rate-limited on every attempt.
  7. Miller WL. Steroid hormone synthesis in mitochondria. — Mol Cell Endocrinol, 2013. PMID 23628605.Title-level only, via opened PubMed search-listing page; abstract page not independently opened this session.
  8. Kimura T. Transduction of ACTH signal from plasma membrane to mitochondria. — J Steroid Biochem, 1986. PMID 3027455.Title-level only.
  9. Igarashi Y, Kimura T. ACTH-mediated changes in rat adrenal mitochondrial phospholipids. — J Biol Chem, 1984. PMID 6088515.Title-level only.
  10. Mukai K, et al. Cholesterol accumulation in adrenocortical mitochondria after ACTH-stimulation. — Endocrinol Jpn, 1984. PMID 6086296.Title-level only.
  11. Abidi P, et al. Oxidative stress-induced inhibition of adrenal steroidogenesis requires participation of p38 mitogen-activated protein kinase signaling pathway. — J Endocrinol, 2008. PMID 18417530.Title-level only.
  12. Evans GW, Wiederanders RE. Pituitary-adrenal regulation of ceruloplasmin. — Nature, 1967. PMID 4293849.Title-level only.
  13. Evans GW, Wiederanders RE. Effect of hormones on ceruloplasmin and copper concentrations in the plasma of the rat. — Am J Physiol, 1968. PMID 4296672.Title-level only.
  14. Bhathena SJ, Werman MJ, Turnlund JR. Opioid Peptides, Adrenocorticotrophic Hormone and Dietary Copper Intake in Humans. — Nutr Neurosci, 1998. PMID 27405911.Title-level only; causal direction (dietary copper intake affecting ACTH/opioid peptide levels, vs. the reverse) could not be confirmed from the title and is not resolved either way in the Copper entry (Hard Rule 4).
  15. Guo W, et al. Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease. — J Int Med Res, 2018. PMID 28851260.Title-level only; cohort is patients with endogenous ACTH-dependent Cushing's disease, not corticotropin-treated patients, class/mechanistic extrapolation for this drug, not this drug's own cohort.
  16. Wan GJ, Niewoehner J, Hayes M. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence. — ClinicoEconomics and Outcomes Research, 2023. PMID 37397803.Title-level only; background/context source, not relied on for any graded claim.
  17. Philbin M, Niewoehner J, Wan GJ. Clinical and Economic Evaluation of Repository Corticotropin Injection. — Advances in Therapy, 2017. PMID 28660550.Title-level only; background/context source, not relied on for any graded claim.
  18. Weber K, Bruck P, Mikes Z, Kupper J, Klingenspor M, Wiesner R. Glucocorticoid hormone stimulates mitochondrial biogenesis specifically in skeletal muscle. — Endocrinology, 2002, 143(1):177-184. DOI 10.1210/en.143.1.177. Rat and cultured mouse-cell study. Abstract reconstructed via the OpenAlex API (abstract_inverted_index) after Crossref bibliographic search located the title; also confirmed as green open access via Unpaywall.Glucocorticoid hormone administered directly, not ACTH/corticotropin; class extrapolation for this drug (Tier C).
  19. Li M, Wang Y, Huang H, Sun H, Gao M, et al. CD163+ macrophages coordinate erythroblastic Island formation and iron metabolism to enable glucocorticoid-induced erythropoiesis. — Biomarker Research, 2026. DOI 10.1186/s40364-026-00936-w. Single-cell sequencing, molecular assays, mouse models, and ex vivo human bone marrow (autoimmune hemolytic anemia patients). Abstract reconstructed via the OpenAlex API single-work lookup by PMID (42365354).General glucocorticoid exposure, not corticotropin/ACTH administration itself; class extrapolation for this drug (Tier C). Underlies both the Iron and Oxygen delivery/utilization entries; see Overlap map.
  20. Macecková Z, Kubíckova A, De Sanctis JB, Hajduch M. Effect of Glucocorticosteroids in Diamond-Blackfan Anaemia: Maybe Not as Elusive as It Seems. — International Journal of Molecular Sciences, 2022. PMID 35163808. DOI 10.3390/ijms23031886. Narrative review of glucocorticoid mechanisms in Diamond-Blackfan anemia. Abstract reconstructed via the OpenAlex API single-work lookup by PMID.General glucocorticoid class, not corticotropin/ACTH specifically; class extrapolation for this drug (Tier C).
  21. Shi J, Ge H, Yang Z, Zhan H. Qigu capsule alleviates dexamethasone-induced muscle dysfunction through mitochondrial biogenesis. — Journal of Traditional Chinese Medicine, 2025, 45(4):739-746. PMID 40810219. DOI 10.19852/j.cnki.jtcm.2025.04.004. Mouse model, dexamethasone 1 mg/kg intraperitoneally daily for six weeks. Abstract reconstructed via the OpenAlex API single-work lookup by PMID.Dexamethasone, not corticotropin/ACTH, was the study drug; class extrapolation for this drug (Tier C).
  22. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis. — Annals of Internal Medicine, 1996. PMID 8967706. DOI 10.7326/0003-4819-125-12-199612150-00004. Two-year randomized, double-blind, placebo-controlled trial, 96 rheumatoid arthritis patients on low-dose prednisone. Abstract reconstructed via the OpenAlex API single-work lookup by PMID.Prednisone, not corticotropin/ACTH, was the study drug; class extrapolation for this drug (Tier C).